co-sponsored byneurosciencecme.com/chairsummit/pdf/mm042-day2-1515-lisanby… · sarah...
TRANSCRIPT
![Page 1: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/1.jpg)
Co-sponsored by
September 26 – 28, 2013 | Westin Tampa Harbour Island
![Page 2: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/2.jpg)
Best Practices in the Management of Geriatric Depression
Sarah Hollingsworth Lisanby, MD Duke University School of Medicine Durham, NC
Alan F. Schatzberg, MD Stanford University School of Medicine Stanford, CA
![Page 3: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/3.jpg)
Sarah Hollingsworth Lisanby, MD
● Grants: Brainsway Ltd.; NeoSync Inc. ● Equipment Support: Magstim; MagVenture, Inc.
Disclosures
![Page 4: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/4.jpg)
Alan F. Schatzberg, MD
● Research/Grants: Sunovion Pharmaceuticals Inc. ● Speakers Bureau: Merck & Co., Inc. ● Consultant: Bay City Capital LLC; CeNeRx BioPharma;
Cervel Neurotech, Inc.; Eli Lilly and Company; Genentech, Inc.; Gilead; Lundbeck/Takeda Pharmaceuticals U.S.A., Inc.; McKinsey & Company; Merck & Co., Inc ; MSI Pharma; Neuronetics Inc.; PharmaNeuroBoost; Xhale, Inc.
● Equity: Amnestix, Inc.; BrainCells Inc.; Cervel Neurotech, Inc.; Corcept Therapeutics; Delpor, Inc.; Forest Laboratories, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Pfizer Inc.; Xhale, Inc.
● Intellectual Property: Named inventor on pharmacogenetic and antiglucocorticoid use patents on prediction of antidepressant response.
Disclosures
![Page 5: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/5.jpg)
Learning Objective
Use validated assessment tools to detect and measure the severity of geriatric depression
1
![Page 6: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/6.jpg)
Learning Objective
Implement treatment for geriatric depression based on evidence-based best practice
2
![Page 7: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/7.jpg)
Geriatric Depression
● Common ● Treatable ● Underdiagnosed
and undertreated ● Significant disease
burden ! Morbidity ! Mortality
![Page 8: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/8.jpg)
Prevalence of Elderly Depression in Different Care Settings
Barua A, et al. Annals of Saudi Medicine. 2011;31(6):620-624. PMID: 22048509.
Care setting
Prevalence of depressive symptoms
Prevalence of major depressive
disorder Community 15% 1% - 3%
Primary care 20% 10% - 12%
Acute hospital 20% - 25% 10% - 15%
Long-term care 30% - 40% 16%
![Page 9: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/9.jpg)
Why Treat Geriatric Depression? ● Increased disability ● Substantially increases the likelihood of death from physical
illnesses ● Increased impairment from a medical disorder ● When untreated, interferes with a patient's ability to follow a
necessary treatment regimen ● Increased use of health care resources ● Increased healthcare costs
! Healthcare costs of elderly people ! 50% higher than those of nondepressed seniors
● Lasts longer in older persons Ellison JM, et al. Psychiatric Clin N Am. 2012;35(1):203-229. PMID: 22370499.
![Page 10: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/10.jpg)
Geriatric Depression: Bio, Psycho, Social Determinants
● BIOLOGICAL ! Genetic
! High prevalence in first-degree relatives
! High concordance in monozygotic twins
! Medical illness ! Vascular changes in the brain ! Chronic or severe pain ! Previous history of depression
● PSYCHOLOGICAL ! Traumatic experiences ! Damage to body image ! Fear of death ! Frustration with memory loss ! Role transitions
Ellison JM, et al. Psychiatric Clin N Am. 2012;35(1):203-229. PMID: 22370499.
● SOCIAL ! Loneliness, isolation ! Recent bereavement ! Lack of a supportive social
network ! Decreased mobility ! Due to illness or loss of driving
privileges
![Page 11: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/11.jpg)
Major Depression in Neurologic Disorders Associated with Aging ● Stroke 40% -60% ● Parkinson disease 30-40% ● Alzheimer’s disease 20% - 40%
Valkanova V, et al. Biol Psychiatry. 2013;73(5):406-413. PMID: 23237315.
![Page 12: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/12.jpg)
Medications That May Cause Depressive Symptoms
● Anabolic steroids ● Anti-arrhythmic
medications ● Anticonvulsant
medications ● Barbiturates ● Benzodiazepines ● Carbidopa or levodopa ● Certain beta-adrenergic
antagonists
● Clonidine ● Cytokines
(specifically IL-2) ● Digitalis preparations ● Glucocorticoids
(prednisone) ● H2 blockers ● Metoclopramide ● Opioids
![Page 13: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/13.jpg)
Factors That Complicate the Diagnosis of Geriatric Depression
● Presentation ! Low/depressed mood need not be present ! Persistent loss of pleasure and interest in previously
enjoyable activities (anhedonia) must be present ! Masked depression or depression without sadness
– mainly somatic complaints ! Often co-occurs with other serious illnesses
● Patient factors ! Think depressive symptoms are a normal part of aging ! Reject diagnosis of depression
![Page 14: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/14.jpg)
Clinical Presentation of Geriatric Depression
● Compared with young persons who are depressed, older persons with depression have: ! Less disturbed sleep (19% vs. 25%) ! Less appetite disturbance (16% vs. 27%) ! Less disturbed energy (11% vs. 18%) ! Less guilt (5% vs. 13%) ! Less diminished concentration (8% vs. 16%) ! Fewer thoughts about death (22% vs. 31%)
Weissman M, et al. Affective Disorders. In Psychiatric Disorders in America 1991.
![Page 15: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/15.jpg)
Geriatric Depression: Assessment Tools
● Geriatric Depression Scale (GDS) ! Validated, 15-item scale ! Scoring: > 5 points or positive responses is diagnostic
● Cornell Scale for Depression in Dementia ! Scoring: > 12 means probable depression
● Center for Epidemiologic Studies of Depression Scale (CES-D)
● Patient Health Questionnaire—9 (PHQ-9) ! 9-item scale ! Self-rated
Dennis M, et al. Age Ageing. 2012;41(2):148-154. PMID: 22236655.
![Page 16: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/16.jpg)
Geriatric Depression Scale (GDS)
● Validated, standardized scale available locally for screening of depression ● Cut-off point of 8/15 ● Can be used by trained nonmedical
personnel
Yesavage J, et al. J Psychiatr Res. 1982;17(1):37-49. PMID: 7183759.
![Page 17: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/17.jpg)
Geriatric Depression Scale (GDS): Short Form Questions Choose the best answer for how you have felt over the past week: 1. Are you basically satisfied with your life? 2. Have you dropped many of your activities and interests? 3. Do you feel that your life is empty? 4. Do you often get bored? 5. Are you in good spirits most of the time? 6. Are you afraid that something bad is going to happen
to you? 7. Do you feel happy most of the time? 8. Do you often feel helpless?
Yesavage J, et al. J Psychiatr Res. 1982;17(1):37-49. PMID: 7183759.
![Page 18: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/18.jpg)
Geriatric Depression Scale (GDS): Short Form Questions 9. Do you prefer to stay at home, rather than going out and
doing new things?
10. Do you feel you have more problems with memory than most?
11. Do you think it is wonderful to be alive now?
12. Do you feel pretty worthless the way you are now?
13. Do you feel full of energy?
14. Do you feel that your situation is hopeless?
15. Do you think that most people are better off than you are?
Yesavage J, et al. J Psychiatr Res. 1982;17(1):37-49. PMID: 7183759.
![Page 19: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/19.jpg)
Differential Diagnosis Depression vs. Dementia
DEPRESSION ● Subacute onset ● Family recognition early ● Rapid progression ● Impairment inconsistent
over time ● Patient admits deficits
DEMENTIA ● Insidious onset ● Delayed family recognition ● Slow progression ● Impairment consistent;
slow, gradual decline ● Patient denies or is
unaware of deficits
Naismith SL, et al. Prog Neurobiol. 2012;98(1):99-143. PMID: 22609700.
![Page 20: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/20.jpg)
Differential Diagnosis Depression vs. Dementia (cont’d)
DEPRESSION ● Appears depressed ● Anhedonia ● Abstract thought usually
normal ● “I don’t know” response to
questions ● Patient often unconcerned
DEMENTIA ● Not depressed ● Can experience pleasure ● Abstract thought impaired ● Near-miss answers ● Patient tries to cover up
Naismith SL, et al. Prog Neurobiol. 2012;98(1):99-143. PMID: 22609700.
![Page 21: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/21.jpg)
Antidepressants in Older Patients
● All antidepressants are equally efficacious ● SSRIs are better tolerated than TCAs ● Escitalopram, citalopram, sertraline, venlafaxine, and
mirtazapine may have fewer drug interactions ● SSRI-related side effects seen in older persons
! Extrapyramidal side effects ! Apathy ! Anorexia ! SIADH ! Upper GI bleeding
SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; SIADH = syndrome of inappropriate antidiuretic hormone; GI = gastrointestinal. Boyce RD, et al. J Am Med Dir Assoc. 2012;13(4):326-331. PMID: 22019084.
![Page 22: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/22.jpg)
Using Antidepressants in Older Patients
● Start low and go slow ● SSRIs are used at the same dose as adults ● Response time is longer in elderly,
> 6 – 12 weeks ● Because of higher risk of relapse in older
persons, continue antidepressants for > 2 years after remission of major depressive disorder
Boyce RD, et al. J Am Med Dir Assoc. 2012;13(4):326-331. PMID: 22019084.
![Page 23: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/23.jpg)
Nonmedical Interventions
● Balanced diet ● Fluids ● Exercise ● Avoid alcohol ● Family support/
social support ● Focus on positives ● Promote autonomy
● Promote creativity ● Alternative therapy
(e.g., pet therapy) ● Pace appropriately ● Inform about
depression ● Avoid stressors
Ellison JM, et al. Psychiatric Clin N Am. 2012;35(1):203-229. PMID: 22370499.
![Page 24: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/24.jpg)
What Do We Know About Elderly Suicide?
● Higher rate, higher lethality, greater determination, and fewer warning signs1
● Risk factors: past history of suicide, physical illness, psychiatric illness, and certain personality traits1
● Majority make contact with a primary care physician one month before their suicide (but not necessarily for a mood problem), and most remain undetected2
● Paradoxically, risk increases as patient begins to respond to treatment2
1 Conwell Y, et al, Biol Psychiatry. 2002;52(3):193-204. PMID: 12182926. 2 Chiu HF, et al. Acta Psychiatr Scand. 2004;109(4):299-305. PMID: 15008804.
![Page 25: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/25.jpg)
Centers for Disease Control and Prevention [CDC] National Center for Health Statistics; National Institute of Mental Health. CDC Website. http://www.cdc.gov/violenceprevention/suicide/statistics/trends02.html. 2013
National Suicide Statistics at a Glance
![Page 26: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/26.jpg)
What Is the Most Effective and Rapidly Acting Treatment for a Suicidal,
Depressed Older Person?
![Page 27: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/27.jpg)
ECT for Depression
● ECT vs. sham ! N = 256 ! Effect size 0.91
● ECT vs. medication ! N = 1,144 ! Effect size 0.80
● Consortium for Research on ECT (CORE) ! N = 217 ! Response rate 75%
Lisanby SH. N Engl J Med. 2007;357(19):1939-1945. PMID: 17989386.; UK ECT Review Group. Lancet. 2003;361(9360):799-808.PMID: 12642045.; Husain MM, et al. J Clin Psychiatry. 2004;65(4):485-491. PMID: 15119910.
![Page 28: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/28.jpg)
Relief of Suicidal Intent by ECT: Relief Is Rapid
HRSD24 = Hamilton Depression Rating Scale, 24-item. Kellner PT, et al. Am J Psychiatry. 2005;162:977-998. PMID: 15863801.
0�
20�
40�
60�
80�
100�
120�
140�
3, 4�
Num
ber
of S
ubje
cts W
hose
Sui
cide
Scor
e Re
solv
ed to
Zer
o��
Baseline HRSD24 Suicide Item (Item #3) Score �
N = 106/131 (81%)
HRDS Suicide Score of 3, 4
![Page 29: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/29.jpg)
Relief of Suicidal Intent by ECT: Number of ECT Needed
Kellner PT, et al. Am J Psychiatry. 2005;162:977-998. PMID: 15863801.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1 2 3 4 5 6 7 8 9 10 11 12 Number of Treatments
% patients reaching 0
Cumulative percent reaching 0
Number of ECT Needed to Resolve Suicide Risk Among All Patients with Baseline Self-Rating ≥ 2
Per
cent
age
of P
atie
nts
Per
cent
age
of p
atie
nts
repo
rting
sui
cida
l tho
ught
s
![Page 30: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/30.jpg)
Limitations of ECT
● Cognitive side effects ! New brain stimulation interventions offer safer
alternatives ● Post-ECT relapse ! Novel maintenance strategies offer sustained
benefit
Lisanby SH. N Engl J Med. 2007;357(19):1939-1945. PMID: 17989386.
![Page 31: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/31.jpg)
New Treatments on the Horizon
● Transcranial magnetic stimulation (TMS) ● Transcranial direct current stimulation
(tDCS)
![Page 32: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/32.jpg)
Prolonging Remission in Depressed Elderly (PRIDE)
![Page 33: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/33.jpg)
Sponsor & DSMB
Clinical Centers
PI: Kellner Hoboken: Greenberg
PI: Lisanby
PI: Young PI: Sampson
PI: Petrides
PI: Husain
PI: McCall
Data Coordinating
Center
PI: Knapp
Clinical Coordinating Centers Multiple-PI: Kellner Multiple-PI: Lisanby
![Page 34: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/34.jpg)
PRIDE Study
● Prolonging Remission in Depressed Elderly ● Aims ! To compare the efficacy of PHARM (Li+VLF)
versus STABLE (flexible, continuation ECT plus Li+VLF) in maintaining remission in late-life depression
! To compare the functional outcomes and tolerability, PHARM versus STABLE
Li = lithium; VLF=venlafaxine. Borroughs H, et al. Fam Pract. 2006;23(3):369-377. PMID: 16476699
![Page 35: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/35.jpg)
Facilitation of Performance in a Working Memory Task With Rtms Stimulation of the Precuneus
• N = 44 • Dose-finding study, within-subject cross-over • 5 Hz TMS to precuneus during retention phase
reduced RT by 50 ms
Luber B, et al. Brain Res. 2007;12;1128(1):120-129. PMID: 17113573.
Day 1 Day 2 Day 3 Day 4
TMSFrontal
ShamFrontal
TMSParietal
ShamParietal
Block 1 Block 2 Block 3 Block 4 Block 5 Block 6
Retention1 Hz
Retention5 Hz
Retention20 Hz
Probe1 Hz
Probe5 Hz
Probe20 Hz
![Page 36: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/36.jpg)
Remediation of Sleep-Deprivation-Induced Working Memory Impairment With fMRI-Guided Transcranial Magnetic Stimulation (TMS)
● Within-subject cross-over ● 5 Hz TMS to superior occipital gyrus reduced RT by 143 ms ● Effect specific to sleep-deprived state, not seen in sleep replete ● Degree of improvement correlated with network expression
Sleep-deprived 60 hrs, N = 15. Luber B, et al. Cereb Cortex. 2008;18(9):2077-2085. PMID:18203694.
Set size 6
r = - 0.58, p < 0.025
Tues 8 AM
Sleep Deprivation
Thurs 12 PM
TMS
Cerebral Cortex
![Page 37: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/37.jpg)
Transcranial Direct Current Stimulation ● Direct current (1 mA) polarizes cortex ● Anodal facilitates, cathodal inhibits ● Effects last hrs ● Safe, painless ● Enhances verbal fluency, word recall,
recovery of function post-stroke ● Cheap, portable
Columbia Brain Stimulation & Therapeutic Modulation Division.
![Page 38: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/38.jpg)
Questions & Answers
![Page 39: Co-sponsored byneurosciencecme.com/chairsummit/PDF/MM042-day2-1515-Lisanby… · Sarah Hollingsworth Lisanby, MD Grants: Brainsway Ltd.; NeoSync Inc. Equipment Support: Magstim; MagVenture,](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff95381ca0716c33b516a/html5/thumbnails/39.jpg)
Co-sponsored by